Table 2.
Baseline demographics of study subjects after PSM.
| Characteristics | VA (N = 78), n (%) | VBQT (N = 78), n (%) | P value |
|---|---|---|---|
| Gender | |||
| Male | 37 (47.4) | 39 (50.0) | .749 |
| Female | 41 (52.6) | 39 (50.0) | |
| Age (years, mean ± SD) | 42.38 ± 11.34 | 44.05 ± 13.44 | .404 |
| Patient type | |||
| Outpatient | 51 (65.4) | 50 (64.1) | .867 |
| Inpatient | 27 (34.6) | 28 (35.9) | |
| BMI | 23.83 ± 2.99 | 23.96 ± 2.99 | .794 |
| Smoking | 15 (19.2) | 11 (14.1) | .390 |
| Alcohol drinking | 23 (29.5) | 25 (32.1) | .729 |
| Number of comorbidities | |||
| 0 | 66 (84.6) | 65 (83.3) | 1.000 |
| 1 | 11 (14.1) | 11 (14.1) | |
| 2 | 1 (1.3) | 2 (2.6) | |
| Endoscopic findings | |||
| No gastroscopy | 26 (33.3) | 33 (42.3) | .639 |
| Only non-atrophic gastritis | 24 (30.8) | 17 (21.8) | |
| Only atrophic gastritis | 22 (28.2) | 20 (25.6) | |
| Mainly gastritis and esophagitis | 2 (2.6) | 2 (2.6) | |
| Mainly gastritis and gastric ulcer and/or duodenal ulcer | 4 (5.1) | 6 (7.7) | |
Student t test, Chi-square and Fisher’s exact tests was used for statistical analysis. All results were considered significant if the P value was < .05.
BMI = body mass index, PSM = propensity score matching, SD = standard deviation, VA = vonoprazan-amoxicillin dual therapy, VBQT = Vonoprazan-based bismuth-containing quadruple therapy.